Core Viewpoint - Yifan Pharmaceutical (002019) has confirmed that its self-developed project Yilishu has recognized intangible assets and made impairment provisions for the fiscal year 2023, with no impairment signs detected so far [1] Group 1 - The company has reported that its ongoing research project F-652 is still in the development process and has not shown any signs of impairment this year [1]

证券日报网讯亿帆医药（002019）11月25日在互动平台回答投资者提问时表示，截至2025年11月20日公 司股东户数为48720户。 ...

Group 1 - The core point of the article is that Yifan Pharmaceutical has entered the medical insurance system in Germany [2] Group 2 - Investors inquired about the status of Yifan Pharmaceutical's entry into the medical insurance system in Germany [2] - Yifan Pharmaceutical confirmed its entry into the medical insurance system on November 25 [2]

Core Viewpoint - The company clarified that the sales commission from the U.S. market for the third quarter of 2025 will be based on the net sales revenue provided by its U.S. partner for that quarter [2]. Group 1 - The company, Yifan Pharmaceutical (002019.SZ), confirmed that its product Yilishu will officially start selling in the U.S. terminal market in the third quarter of 2025 [2]. - The sales commission reported for the third quarter of 2025 corresponds to the net sales revenue generated by the U.S. partner in that same quarter [2].

Group 1 - The company has confirmed that its self-developed project Yili Shou has recognized intangible assets and made impairment provisions in the 2023 fiscal year, with no signs of impairment detected this year [2] - The company's research project F-652 is still in the development process this year, and no signs of impairment have been found [2]

（记者 胡玲） 亿帆医药（002019.SZ）11月25日在投资者互动平台表示，截至目前，F627在中、美、德三个国家正式 上市销售。 每经AI快讯，有投资者在投资者互动平台提问：请问截至目前，F627已经真正进入了多少个国家并正 式开始销售？ ...

格隆汇11月25日丨亿帆医药(002019.SZ)在投资者互动平台表示，合成生物项目处于竣工验收调试阶 段。 （原标题：亿帆医药(002019.SZ)：合成生物项目处于竣工验收调试阶段） ...

免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 董秘你在回复有关F652在临床试验推进沟通的问题已经长达四年了，在这个沟通过程中到底是公司管 理层不作为还是相关监管部门不作为呢？不会一直在进行无了期无效的沟通吧？ 投资者提问： 感谢您的关注与提问。2024年4月底亿一生物与监管机构召开了III类咨询沟通会，就在研项目F-652的 ACLF适应症后续临床试验设计的重点内容进行了讨论，公司结合监管机构的要求与建议进行反复论 证，评判风险，并适时动态调整。在国内优先推进确定性较强的aGVHD适应症的后续临床试验，目前 已提交临床试验申请。谢谢！查看更多董秘问答>> 董秘回答(亿帆医药SZ002019)： ...

董秘请问:近期公司的亿立舒收到泰国和马来西亚两国获得注册上市的批准，为什么不发公告呢？你这 样做有没有违反了上市公司有关信息披露的规定？ 董秘回答(亿帆医药SZ002019)： 登录新浪财经APP 搜索【信披】查看更多考评等级 投资者提问： 感谢您的关注与提问。公司根据《深圳证券交易所股票上市规则》、《公司章程》等规定履行信息披露 义务。对于未达到披露标准的，公司也尽量通过官网、投资者关系平台等便于投资者了解更多信息。谢 谢！查看更多董秘问答>> 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 ...

亿帆医药（002019.SZ）11月25日在投资者互动平台表示，国内发货量同比上升。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问亿立舒今年三季度以来在国内的销量是否继续保 持着稳定的增长态势？ ...